{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:05:21Z","timestamp":1793505921040,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ymgme.2024.108608","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:09:19Z","timestamp":1731071359000},"page":"108608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials"],"prefix":"10.1016","volume":"143","author":[{"given":"Jordi","family":"D\u00edaz-Manera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Erdem-\u00d6zdamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Tard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"B\u00e9hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bouhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Houn","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina An","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huynh-Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Periquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Tammireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.108608_bb0005","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2024.108608_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: Acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2024.108608_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108608_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1566524024605789","article-title":"Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)","volume":"2","author":"Raben","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ymgme.2024.108608_bb0025","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.55.8.1122","article-title":"Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation","volume":"55","author":"Laforet","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2024.108608_bb0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2024.108608_bb0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2024.108608_bb0040","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108608_bb0045","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2024.108608_bb0050","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2024.108608_bb0055","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2024.108608_bb0060","series-title":"NEXVIADYME Avalglucosidase Alfa 100 Mg Powder for Concentrate for Solution for Infusion. [Summary of Product Characteristics]","year":"2022"},{"key":"10.1016\/j.ymgme.2024.108608_bb0065","series-title":"NEXVIAZYME (Avalglucosidase Alfa-Ngpt) for Injection, for Intravenous Use. [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ymgme.2024.108608_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2024.108608_bb0075","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2024.108608_bb0080","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymgme.2024.108608_bb0085","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108608_bb0090","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2024.108608_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2024.108608_bb0100","first-page":"e536","article-title":"Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Pompe Dis. Neurol."},{"key":"10.1016\/j.ymgme.2024.108608_bb0105","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108608_bb0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2024.108608_bb0115","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2024.108608_bb0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/WCO.0b013e32834a1e00","article-title":"Challenges in diagnosis and treatment of late-onset Pompe disease","volume":"24","author":"Desnuelle","year":"2011","journal-title":"Curr. Opin. Neurol."},{"issue":"174\u2013180","key":"10.1016\/j.ymgme.2024.108608_bb0125","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108608_bb0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12883-017-0983-2","article-title":"The humanistic burden of Pompe disease: are there still unmet needs? A systematic review","volume":"17","author":"Schoser","year":"2017","journal-title":"BMC Neurol."},{"issue":"1384","key":"10.1016\/j.ymgme.2024.108608_bb0135","first-page":"1386","article-title":"Home therapy for lysosomal storage disorders","volume":"16","author":"Hughes","year":"2007","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2024.108608_bb0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","article-title":"Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up","volume":"39","author":"Gungor","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108608_bb0145","series-title":"Nexviadyme. Summary of Product Characteristics. June 2022","author":"European Medicines Agency (EMA)","year":"2022"},{"key":"10.1016\/j.ymgme.2024.108608_bb0150","doi-asserted-by":"crossref","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","article-title":"Home-based infusion therapy for patients with Fabry disease","volume":"17","author":"Cousins","year":"2008","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2024.108608_bb0155","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2024.108608_bb0160","article-title":"Home infusion therapy for Pompe disease: Recommendations for German-speaking countries","author":"Hahn","year":"2021","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"10.1016\/j.ymgme.2024.108608_bb0165","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.hjdsi.2016.04.004","article-title":"Home infusion: safe, clinically effective, patient preferred, and cost saving","volume":"5","author":"Polinski","year":"2017","journal-title":"Healthc. (Amst)"},{"key":"10.1016\/j.ymgme.2024.108608_bb0170","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","article-title":"Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses","volume":"97","author":"Burton","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108608_bb0175","first-page":"85","article-title":"Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group","volume":"12","author":"Concolino","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2024.108608_bb0180","first-page":"31","article-title":"Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina","volume":"73","author":"Kisinovsky","year":"2013","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ymgme.2024.108608_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2024.108608_bb0190","first-page":"15","article-title":"Home infusion with Elosulfase alpha (Vimizim(R)) in a UK Paediatric setting","volume":"14","author":"Finnigan","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2024.108608_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2016.08.005","article-title":"Home infusion of intravenous velaglucerase alfa: experience from pooled clinical studies in 104 patients with type 1 Gaucher disease","volume":"120","author":"Elstein","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108608_bb0200","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bcmd.2015.09.002","article-title":"13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease","volume":"55","author":"Elstein","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2024.108608_bb0205","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V82.4.1107.1107","article-title":"Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients","volume":"82","author":"Zimran","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2024.108608_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/NAN.0000000000000018","article-title":"Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program","volume":"37","author":"Gregory","year":"2014","journal-title":"J. Infus. Nurs."},{"key":"10.1016\/j.ymgme.2024.108608_bb0215","article-title":"Positive impact of home ERT for mucopolysaccharidoses and Pompe disease: the lesson learnt from the COVID-19 pandemic","volume":"11","author":"Fiumara","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.ymgme.2024.108608_bb0220","article-title":"The patients; perspective on home-based infusion: a longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy","volume":"35","author":"Heinrich","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2024.108608_bb0225","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13023-023-02715-4","article-title":"Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study","volume":"18","author":"Ditters","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"892\u2013894","key":"10.1016\/j.ymgme.2024.108608_bb0230","first-page":"896","article-title":"Intravenous enzyme replacement therapy: hospital vs home","volume":"19","author":"Parini","year":"2010","journal-title":"Br. J. Nurs."}],"updated-by":[{"DOI":"10.1016\/j.ymgme.2024.109006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922400492X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922400492X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:44:20Z","timestamp":1734767060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922400492X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S109671922400492X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108608","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ymgme.2024.109006","asserted-by":"object"}]},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108608"}}